|
|
|
|
Artificial dopamine agonists are widely employed for the treatment of idiopathic parkinsonism.Pleuropulmonary disease has previously been reported to occur with the use of bromocriptine and mesulergine.We report similar adverse effects induced by the newer agonists lisuride and cabergoline.All these agents are tetracyclic ergot derivatives.This suggests a causal link between ergot-derived dopamine agonists and pleuropulmonary disease. |
|